Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;18(9):2275-2277.
doi: 10.1038/s41423-021-00744-2. Epub 2021 Jul 28.

Increase in serum levels of phosphatidylserine-specific phospholipase A1 in COVID-19 patients

Takuya Shimura #  1 , Makoto Kurano #  2   3 , Koh Okamoto  4 , Daisuke Jubishi  4 , Kuniyuki Kano  5 , Koji Igarashi  6 , Satoshi Shimamoto  6 , Junken Aoki  5 , Kyoji Moriya  4 , Yutaka Yatomi  7   8
Affiliations

Increase in serum levels of phosphatidylserine-specific phospholipase A1 in COVID-19 patients

Takuya Shimura et al. Cell Mol Immunol. 2021 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

KI and RS are employees of TOSOH Corporation.

Figures

Fig. 1
Fig. 1
Serum PS-PLA1 levels in subjects with COVID-19. The serum PS-PLA1 levels were measured in patients with COVID-19 (severity level 1, n = 41; severity level 2, n = 62; severity level 3, n = 24) and healthy subjects (n = 58). A Time course of serum PS-PLA1 levels in symptomatic COVID-19 patients and distribution of serum PS-PLA1 levels in healthy subjects. The differences in the levels between the healthy subjects and COVID-19 patients were assessed by the Mann–Whitney U test, *P < 0.01 vs. healthy subjects. Differences between the serum PS-PLA1 levels measured on specified days after the onset of COVID-19 symptoms and those measured after day 21 from symptom onset in individual subjects were assessed by the Wilcoxon signed-rank sum test, †P  0.01 vs. level measured after day 21. B Time course of the serum PS-PLA1 levels in the COVID-19 patients for whom samples collected before disease onset (Pre) were available (n = 7). C–F Time course of serum PS-PLA1 levels in patients with mild (C), moderate (D), and severe COVID-19 (E). *P < 0.01; †P < 0.05 vs. level measured after day 21 from symptom onset. F Differences in the serum PS-PLA1 levels on days 7–8, days 9–10, and days 11–12. The differences were assessed using an independent Kruskal–Wallis test, followed by the Games Howell test for post hoc analysis. *P < 0.01; †P < 0.05. The horizontal bars represent the means of independent samples
See this image and copyright information in PMC

References

    1. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, et al. TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods. 2012;9:1021–9. doi: 10.1038/nmeth.2172. - DOI - PubMed
    1. Bellini F, Bruni A. Role of a serum phospholipase A1 in the phosphatidylserine-induced T cell inhibition. FEBS Lett. 1993;316:1–4. doi: 10.1016/0014-5793(93)81724-E. - DOI - PubMed
    1. Nishikawa M, Kurano M, Ikeda H, Aoki J, Yatomi Y. Lysophosphatidylserine has bilateral effects on macrophages in the pathogenesis of atherosclerosis. J Atheroscler Thromb. 2015;22:518–26. doi: 10.5551/jat.25650. - DOI - PubMed
    1. Frasch SC, Bratton DL. Emerging roles for lysophosphatidylserine in resolution of inflammation. Prog Lipid Res. 2012;51:199–207. doi: 10.1016/j.plipres.2012.03.001. - DOI - PMC - PubMed
    1. Aoki J, Nagai Y, Hosono H, Inoue K, Arai H. Structure and function of phosphatidylserine-specific phospholipase A1. Biochim Biophys Acta. 2002;1582:26–32. doi: 10.1016/S1388-1981(02)00134-8. - DOI - PubMed

Publication types